Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Maisonneuve P, Gatti G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7(12):983–90.

Article  PubMed  Google Scholar 

Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, Skelly JM, Harlow SP, Weaver DL, Mamounas EP, et al. Morbidity results from the NSABP B-32 trial comparing Sentinel Lymph Node Dissection Versus Axillary Dissection. J Surg Oncol. 2010;102(2):111–8.

Article  PubMed  PubMed Central  Google Scholar 

Liang X, Yu J, Wen B, Xie J, Cai Q, Yang Q. MRI and FDG-PET/CT based assessment of axillary lymph node metastasis in early breast cancer: a meta-analysis. Clin Radiol. 2017;72(4):295–301.

Article  CAS  PubMed  Google Scholar 

Mainiero MB, Cinelli CM, Koelliker SL, Graves TA, Chung MA. Axillary Ultrasound and Fine-Needle aspiration in the preoperative evaluation of the breast Cancer patient: an Algorithm based on Tumor size and Lymph Node Appearance. Am J Roentgenol. 2010;195(5):1261–7.

Article  Google Scholar 

Han S, Choi J. Impact of 18F-FDG PET, PET/CT, and PET/MRI on staging and management as an initial staging modality in breast Cancer a systematic review and Meta-analysis. Clin Nucl Med. 2021;46(4):271–82.

Article  PubMed  PubMed Central  Google Scholar 

Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma - A metaanalysis. Cancer. 2006;106(1):4–16.

Article  PubMed  Google Scholar 

Wei WJ, Rosenkrans ZT, Liu JJ, Huang G, Luo QY, Cai WB. ImmunoPET: Concept, Design, and applications. Chem Rev. 2020;120(8):3787–851.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, Tani H, Miyakita Y, Kanayama Y, Wada Y et al.: 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. Ejnmmi Res 2015, 5.

Bai J, Qiu S, Zhang G. Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. SIGNAL Transduct Target THERAPY 2023, 8(1).

Ulaner G, Mankoff D, Clark A, Fowler A, Linden H, Peterson L, Dehdashti F, Kurland B, Mortimer J, Mouabbi J, et al. Summary: Appropriate Use Criteria for Estrogen receptor-targeted PET imaging with 16α-18F-Fluoro-17β-Fluoroestradiol. J Nucl Med. 2023;64(3):351–4.

Article  CAS  PubMed  Google Scholar 

Kurland B, Wiggins J, Coche A, Fontan C, Bouvet Y, Webner P, Divgi C, Linden H. Whole-body characterization of estrogen receptor status in metastatic breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and recommendations for Integration into clinical applications. ONCOLOGIST. 2020;25(10):835–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masuda H, Zhang DW, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136(2):331–45.

Article  CAS  PubMed  Google Scholar 

Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32.

Article  CAS  PubMed  Google Scholar 

Machiels J, Leemans C, Golusinski W, Grau C, Licitra L, Gregoire, Board EE, Comm EG, Board EE. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462–75.

Article  PubMed  Google Scholar 

Bradley J, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. LANCET Oncol. 2015;16(2):187–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, et al. Randomized Phase II study of the anti-epidermal growth factor receptor monoclonal antibody Cetuximab with Cisplatin Versus Cisplatin alone in patients with metastatic triple-negative breast Cancer. J Clin Oncol. 2013;31(20):2586–.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshii Y, Yoneda M, Ikawa M, Furukawa T, Kiyono Y, Mori T, Yoshii H, Oyama N, Okazawa H, Saga T, et al. Radio labeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less ρ0 cells and cybnds carrying MELAS mitochondnal DNA mutation. Nucl Med Biol. 2012;39(2):177–85.

Article  CAS  PubMed  Google Scholar 

Yoshii Y, Yoshimoto M, Matsumoto H, Tashima H, Iwao Y, Takuwa H, Yoshida E, Wakizaka H, Yamaya T, Zhang MR, et al. Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts. Oncotarget. 2018;9(48):28935–50.

Article  PubMed  PubMed Central  Google Scholar 

Watabe T, Kabayama K, Naka S, Yamamoto R, Kaneda K, Serada S, Ooe K, Toyoshima A, Wang Y, Haba H et al. Immuno-PET and targeted α-Therapy using anti-glypican-1 antibody labeled with 89Zr or 211At: a Theranostic Approach for pancreatic ductal adenocarcinoma. J Nucl Med 2023.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.

Article  CAS  PubMed  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H. NCCN Guidelines® insights: breast Cancer, Version 4.2023: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2023;21(6):594–608.

Article  PubMed  Google Scholar 

Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–68.

Article  CAS  PubMed  Google Scholar 

Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res. 2021;40(1):328.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding F, Huang C, Liang CY, Wang C, Liu JJ, Tang DW. 68Ga-FAPI-04 vs.18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2021;49(1):290–300.

Article  CAS  PubMed  Google Scholar 

Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016;35(4):575–88.

Article  CAS  PubMed  PubMed Central  Google Scholar